Bernard Combe

Professor of Rheumatology, Head of the department of Rheumatology, Head of the medical and surgical bones and joint departments

University of Montpellier

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Bernard Combe is a distinguished faculty member at the University of Montpellier and CHU Montpellier, France, where he serves as the Head of the Department of Rheumatology and the Medical and Surgical Bones and Joint Departments. His research focuses on the safety and efficacy of treatment options for rheumatic diseases, including the evaluation of tumor necrosis factor inhibitors and novel therapies for rheumatoid arthritis. His recent publications explore critical topics such as the prognosis of early arthritis phenotypes and the management of immunoglobulin deficiency under specific therapies.

Articles (18)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

Hendrik Schulze‐Koops

GERMANY

View details

Andrea Rubbert-Roth

Prof Dr

Kantonsspital St. Gallen

SWITZERLAND

View details

Claire I Daien

INSERM U1065

FRANCE

View details

Patrick Verschueren

Full Professor

Katholieke Universiteit Leuven

BELGIUM

View details

Alex MacGregor

University of East Anglia

UNITED KINGDOM

View details

Roy Fleischmann

Clinical Professor of Medicine

University of Texas Southwestern Medical Center

UNITED STATES

View details

patrick durez

UCLouvain

BELGIUM

View details

Daniel McWilliams

UNITED KINGDOM

View details

maxime dougados

Université Paris Cité

FRANCE

View details

James Gwinnutt

The University of Manchester

UNITED KINGDOM

View details

Mark Lunt

Reader in Medical Statistics

The University of Manchester

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bernard Combe

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations

Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

Ten-year clinical outcome of recent-onset axial spondyloarthritis: Results from the DESIR inception Cohort

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study

Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort

Should we stop methotrexate or not for vaccination?

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Distinction and prognosis of early arthritis phenotypes: an analysis in three European cohorts

Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis

Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept

Correction to: Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52

Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort

Collaborators (11)

Hendrik Schulze‐Koops

Andrea Rubbert-Roth

Claire I Daien

Patrick Verschueren

Alex MacGregor

Roy Fleischmann

patrick durez

Daniel McWilliams

maxime dougados

James Gwinnutt

Mark Lunt

Make your next move.